Tidal Investments LLC Purchases 5,281 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Tidal Investments LLC increased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 83.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,591 shares of the company’s stock after purchasing an additional 5,281 shares during the period. Tidal Investments LLC’s holdings in IDEXX Laboratories were worth $4,792,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. United Capital Financial Advisors LLC lifted its holdings in shares of IDEXX Laboratories by 0.9% in the 4th quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company’s stock worth $1,011,000 after purchasing an additional 22 shares in the last quarter. Gabelli Funds LLC lifted its holdings in shares of IDEXX Laboratories by 5.3% in the 4th quarter. Gabelli Funds LLC now owns 500 shares of the company’s stock worth $207,000 after purchasing an additional 25 shares in the last quarter. Perigon Wealth Management LLC lifted its holdings in shares of IDEXX Laboratories by 1.8% in the 4th quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company’s stock worth $632,000 after purchasing an additional 26 shares in the last quarter. Summit Trail Advisors LLC lifted its holdings in shares of IDEXX Laboratories by 3.3% in the 4th quarter. Summit Trail Advisors LLC now owns 810 shares of the company’s stock worth $335,000 after purchasing an additional 26 shares in the last quarter. Finally, Forum Financial Management LP lifted its holdings in shares of IDEXX Laboratories by 4.9% in the 4th quarter. Forum Financial Management LP now owns 621 shares of the company’s stock worth $257,000 after purchasing an additional 29 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

IDXX has been the subject of a number of analyst reports. Barclays increased their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Stifel Nicolaus increased their price target on IDEXX Laboratories from $460.00 to $510.00 and gave the company a “hold” rating in a research report on Monday. Piper Sandler increased their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, May 9th. Finally, Bank of America increased their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $536.00.

IDEXX Laboratories Trading Down 0.9%

Shares of IDEXX Laboratories stock opened at $517.16 on Wednesday. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $530.60. The firm has a market cap of $41.59 billion, a PE ratio of 48.47, a P/E/G ratio of 3.41 and a beta of 1.52. The stock has a fifty day moving average price of $435.69 and a 200-day moving average price of $432.77. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The firm had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. During the same period last year, the firm posted $2.71 EPS. The business’s revenue was up 3.6% compared to the same quarter last year. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.